Insight for strategy that delivers

Martine Leroy, Matt Bolton|5th April 2016

Healthcare is changing. Developments in treatments are taking place faster than ever, more stakeholders are involved in making decisions around treatments, and these stakeholders have different, sometimes conflicting needs. In this context, insight is key to effective marketing in meeting the challenge to deliver value to an ever-broadening range of stakeholders.

In this article, Head of Commercial Matt Bolton and Head of Insight Martine Leroy talk through how insight informs strategy at Blue Latitude Health.

What do we mean by ‘insight’?

At Blue Latitude Health, we regard insight as the deep understanding of the space where external and internal customers meet. In this context, we refer to external customers as those making decisions that impact the success of your product or service, be they patients, physicians, payers, nurses or others. Internal customers refer to those members of a healthcare company that must be engaged and motivated to deliver for external customers, from the brand team, to capability leads or compliance. Gathering insight in this sense allows us the opportunity to identify where external customers expect the business to operate and to deliver, and importantly where internal customers want and are able to operate. After all, insight is only useful if it can be acted upon. 

 

Read more about customer-centric strategy and design in issue 2 of Perspective magazine:

Maximising the commercial potential of the pharmaceutical pipeline

Blue Latitude Health|3rd April 2020

Decisions made early in the drug development process can define the limits of what’s possible for products and portfolios. So, why aren’t commercial teams always involved in these early conversations? In this Q&A we deep dive into early stage strategy, including how to break down these siloes and rethink drug development and clinical trial design.

read more

In-progress treatments for COVID-19: an attempt to simplify things

Manos Mastorakis|27th March 2020

Senior Associate Consultant, Manos Mastorakis, takes a look at a number of COVID-19 drugs that are already registered in clinical trials, providing analysis aiming to simplify the current landscape.

read more

Why I became a multiple myeloma patient advocate

Imogen Coupe|6th March 2020

BLH speaks to MM patient advocate, Peter McCleave, to find out how he has fought to remain positive throughout his treatment journey while simultaneously leading a successful campaign to get more people to sign up to be a blood stem cell donor.

read more